reports
- Amira Manai
- Andreas Riemann
A1XEH4 CROSSJECT SA
SBS STRATEC SE
LXS LANXESS AG
HCO HIGHCO SA
IPH INNATE PHARMA SA CLASS A
NTG NETGEM SA
NRG NRJ GROUP SA
LNA LNA SANTE SA
TRI TRIGANO SA
QDT QUADIENT SA
POS PORR AG
FFP FFP
DEZ DEUTZ AG
WIE WIENERBERGER AG
AALB AALBERTS N.V.
FACC FACC AG
SANT S&T AG
RBO ROCHE BOBOIS INTERNATIONAL SAS
JEN JENOPTIK AG
CLA CLARANOVA SE
ALHGR HOFFMANN GREEN CEMENT TECHNOLOGIES SA
MRX MISTER SPEX SE
ARVEN ARVERNE GROUP SA
- Amira Manai
- Andreas Riemann
A1XEH4 CROSSJECT SA
SBS STRATEC SE
LXS LANXESS AG
HCO HIGHCO SA
IPH INNATE PHARMA SA CLASS A
NTG NETGEM SA
NRG NRJ GROUP SA
LNA LNA SANTE SA
TRI TRIGANO SA
QDT QUADIENT SA
POS PORR AG
FFP FFP
DEZ DEUTZ AG
WIE WIENERBERGER AG
AALB AALBERTS N.V.
FACC FACC AG
SANT S&T AG
RBO ROCHE BOBOIS INTERNATIONAL SAS
JEN JENOPTIK AG
CLA CLARANOVA SE
ALHGR HOFFMANN GREEN CEMENT TECHNOLOGIES SA
MRX MISTER SPEX SE
ARVEN ARVERNE GROUP SA
- Martial Descoutures
- Oussema Denguir
- Martial Descoutures
- Oussema Denguir
BVI BUREAU VERITAS SA
ADP AEROPORTS DE PARIS SA
DGE DIAGEO PLC
SU SCHNEIDER ELECTRIC SE
OSE OSE IMMUNOTHERAPEUTICS SA
RI PERNOD RICARD SA
HO THALES SA
RCO REMY COINTREAU SA
EVT EVOTEC SE
MF WENDEL SE
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
ABVX ABIVAX SA
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
ISP INTESA SANPAOLO S.P.A.
GNFT GENFIT SA
UCG UNICREDIT S.P.A.
SIGHT GENSIGHT BIOLOGICS SA
ADOC ADOCIA SA
FYB FORMYCON AG
GLPG GALAPAGOS NV
ALVAL VALBIOTIS SA
MOL MOL HUNGARIAN OIL & GAS PLC CLASS A
MEDCL MEDINCELL SA
CPR DAVIDE CAMPARI-MILANO N.V.
AELIS AELIS FARMA SA
BAI BENEVOLENTAI
OSE OSE IMMUNOTHERAPEUTICS SA
EVT EVOTEC SE
MF WENDEL SE
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
ABVX ABIVAX SA
ALDEL DELFINGEN INDUSTRY SA
IPH INNATE PHARMA SA CLASS A
VIRP VIRBAC SA
VLS VALNEVA SE
GBT GUERBET SA
GOE GROUPE GORGE SA
ISP INTESA SANPAOLO S.P.A.
TIETO TIETOEVRY OYJ
GNFT GENFIT SA
SESL SES-IMAGOTAG SA
UCG UNICREDIT S.P.A.
SIGHT GENSIGHT BIOLOGICS SA
ADOC ADOCIA SA
FYB FORMYCON AG
FLU FLUGHAFEN WIEN AG
GLPG GALAPAGOS NV
ALVAL VALBIOTIS SA
MEDCL MEDINCELL SA
UPG UNIFIEDPOST GROUP
ECMPA EUROCOMMERCIAL PROPERTIES NV
AELIS AELIS FARMA SA
BAI BENEVOLENTAI
OSE OSE IMMUNOTHERAPEUTICS SA
EVT EVOTEC SE
MF WENDEL SE
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
ABVX ABIVAX SA
ALDEL DELFINGEN INDUSTRY SA
IPH INNATE PHARMA SA CLASS A
VIRP VIRBAC SA
VLS VALNEVA SE
GBT GUERBET SA
GOE GROUPE GORGE SA
ISP INTESA SANPAOLO S.P.A.
TIETO TIETOEVRY OYJ
GNFT GENFIT SA
SESL SES-IMAGOTAG SA
UCG UNICREDIT S.P.A.
SIGHT GENSIGHT BIOLOGICS SA
ADOC ADOCIA SA
FYB FORMYCON AG
FLU FLUGHAFEN WIEN AG
GLPG GALAPAGOS NV
ALVAL VALBIOTIS SA
MEDCL MEDINCELL SA
UPG UNIFIEDPOST GROUP
ECMPA EUROCOMMERCIAL PROPERTIES NV
AELIS AELIS FARMA SA
BAI BENEVOLENTAI
BVI BUREAU VERITAS SA
ADP AEROPORTS DE PARIS SA
DGE DIAGEO PLC
SU SCHNEIDER ELECTRIC SE
OSE OSE IMMUNOTHERAPEUTICS SA
RI PERNOD RICARD SA
HO THALES SA
RCO REMY COINTREAU SA
EVT EVOTEC SE
MF WENDEL SE
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
ABVX ABIVAX SA
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
ISP INTESA SANPAOLO S.P.A.
GNFT GENFIT SA
UCG UNICREDIT S.P.A.
SIGHT GENSIGHT BIOLOGICS SA
ADOC ADOCIA SA
FYB FORMYCON AG
GLPG GALAPAGOS NV
ALVAL VALBIOTIS SA
MOL MOL HUNGARIAN OIL & GAS PLC CLASS A
MEDCL MEDINCELL SA
CPR DAVIDE CAMPARI-MILANO N.V.
AELIS AELIS FARMA SA
BAI BENEVOLENTAI
- Team Pharma
EVT EVOTEC SE
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
ABVX ABIVAX SA
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
GNFT GENFIT SA
SIGHT GENSIGHT BIOLOGICS SA
ADOC ADOCIA SA
FYB FORMYCON AG
GLPG GALAPAGOS NV
ALVAL VALBIOTIS SA
MEDCL MEDINCELL SA
AELIS AELIS FARMA SA
BAI BENEVOLENTAI
- Team Pharma
EVT EVOTEC SE
A1XEH4 CROSSJECT SA
TNG TRANSGENE SA
ABVX ABIVAX SA
IPH INNATE PHARMA SA CLASS A
VLS VALNEVA SE
GNFT GENFIT SA
SIGHT GENSIGHT BIOLOGICS SA
ADOC ADOCIA SA
FYB FORMYCON AG
GLPG GALAPAGOS NV
ALVAL VALBIOTIS SA
MEDCL MEDINCELL SA
AELIS AELIS FARMA SA
BAI BENEVOLENTAI
- Maria Vara
- Oscar Haffen Lamm
- Valliant Campagne
- Jerôme Bodin
- Thomas Zlowodzki
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
AAL ANGLO AMERICAN PLC
RNO RENAULT SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
EO FAURECIA SA
OSE OSE IMMUNOTHERAPEUTICS SA
SSAB A SSAB AB CLASS A
DAI DAIMLER AG
POM PLASTIC OMNIUM SE
SZG SALZGITTER AG
TYRES NOKIAN RENKAAT OYJ
HCO HIGHCO SA
PSM PROSIEBENSAT.1 MEDIA SE
IPH INNATE PHARMA SA CLASS A
NTG NETGEM SA
LNA LNA SANTE SA
GBT GUERBET SA
VOE VOESTALPINE AG
ALCAR CARMAT SA
ACX ACERINOX SA
TRI TRIGANO SA
FR VALEO SE
G24 SCOUT24 AG
VOW3 VOLKSWAGEN AG PREF
ERA ERAMET SA
QDT QUADIENT SA
POS PORR AG
NDA AURUBIS AG
CAI CA IMMOBILIEN ANLAGEN AG
CIE CIE AUTOMOTIVE S.A.
MONT MONTEA SCA
SLIGR SLIGRO FOOD GROUP N.V.
KTCG KAPSCH TRAFFICCOM
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
SEFER SERGEFERRARI GROUP SA
ALBFR SIDETRADE SA
FYB FORMYCON AG
SMHN SUESS MICROTEC AG
FACC FACC AG
RACE FERRARI NV
RIO RIO TINTO PLC
BHP BHP GROUP LTD
PIRC PIRELLI & C. S.P.A.
JST JOST WERKE AG
AMAG AMAG AUSTRIA METALL AG
VOS VOSSLOH AG
UMI UMICORE
GEST GESTAMP AUTOMOCION S.A.
2CRSI 2CRSI SA
RBO ROCHE BOBOIS INTERNATIONAL SAS
ALCUR ARCURE SA
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
STLA STELLANTIS N.V.
FAST FASTNED
ALAFY AFYREN
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
LHYFE LHYFE S.A.
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
IOS IONOS GROUP SE
TUI TUI AG
DSFIR KONINKLIJKE DSM N.V.
R3NK RENK GROUP AG
ARVEN ARVERNE GROUP SA
ALIV SDB AUTOLIV INC.
BRE BREMBO S.P.A.
- Martial Descoutures
- Oussema Denguir
- Jerôme Bodin
- Thomas Zlowodzki
BMW BAYERISCHE MOTOREN WERKE AKTIENGESELLSCHAFT
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
AAL ANGLO AMERICAN PLC
RNO RENAULT SA
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
EO FAURECIA SA
OSE OSE IMMUNOTHERAPEUTICS SA
SSAB A SSAB AB CLASS A
DAI DAIMLER AG
POM PLASTIC OMNIUM SE
SZG SALZGITTER AG
TYRES NOKIAN RENKAAT OYJ
HCO HIGHCO SA
PSM PROSIEBENSAT.1 MEDIA SE
IPH INNATE PHARMA SA CLASS A
NTG NETGEM SA
LNA LNA SANTE SA
GBT GUERBET SA
VOE VOESTALPINE AG
ALCAR CARMAT SA
ACX ACERINOX SA
TRI TRIGANO SA
FR VALEO SE
G24 SCOUT24 AG
VOW3 VOLKSWAGEN AG PREF
ERA ERAMET SA
QDT QUADIENT SA
POS PORR AG
NDA AURUBIS AG
CAI CA IMMOBILIEN ANLAGEN AG
CIE CIE AUTOMOTIVE S.A.
MONT MONTEA SCA
SLIGR SLIGRO FOOD GROUP N.V.
KTCG KAPSCH TRAFFICCOM
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
SEFER SERGEFERRARI GROUP SA
ALBFR SIDETRADE SA
FYB FORMYCON AG
SMHN SUESS MICROTEC AG
FACC FACC AG
RACE FERRARI NV
RIO RIO TINTO PLC
BHP BHP GROUP LTD
PIRC PIRELLI & C. S.P.A.
JST JOST WERKE AG
AMAG AMAG AUSTRIA METALL AG
VOS VOSSLOH AG
UMI UMICORE
GEST GESTAMP AUTOMOCION S.A.
2CRSI 2CRSI SA
RBO ROCHE BOBOIS INTERNATIONAL SAS
ALCUR ARCURE SA
AML ASTON MARTIN LAGONDA GLOBAL HOLDINGS
STLA STELLANTIS N.V.
FAST FASTNED
ALAFY AFYREN
ML COMPAGNIE GENERALE DES ETABLISSEMENTS MICHELIN
LHYFE LHYFE S.A.
P911 DR. ING. H.C. F. PORSCHE AKTIENGESELLSCHAFT
IOS IONOS GROUP SE
TUI TUI AG
DSFIR KONINKLIJKE DSM N.V.
R3NK RENK GROUP AG
ARVEN ARVERNE GROUP SA
ALIV SDB AUTOLIV INC.
BRE BREMBO S.P.A.
- Martial Descoutures
- Oussema Denguir
Innate Pharma organise une conference telephonique et un webcast pour ...
MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») a annoncé aujourd'hui qu'elle organisera une conférence téléphonique le jeudi 27 mars 2025 à 14H00 CET / 9H00 EDT à la suite de la publication de ses résultats financiers pour l’exercice clos le 31 décembre 2024. La conférence sera animée par : Jonathan Dickinson, Président du Directoire Sonia Quaratino, Vice-président exécutif, Directeur Médical Yannis Morel, Vice-président exécutif, Directeur des Opérations Frédéric Lombard, Vice-président sen...
Innate Pharma Announces Conference Call and Webcast for Full Year 2024...
MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announces that the Company will hold a conference call on Thursday, March 27, 2025 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2024. Participants during the call will be: Jonathan Dickinson, Chief Executive Officer Sonia Quaratino, Executive Vice President, Chief Medical Officer Yannis Morel, Executive Vice President, Chief Operating Officer Frédéric Lombard, Senior Vice Presi...
Innate Pharma annonce sa participation à la 2025 Leerink Partners Glob...
MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris : IPH ; Nasdaq : IPHA) (« Innate » ou la « Société ») annonce aujourd’hui que son équipe de direction présentera et animera des réunions lors de la 2025 Leerink Partners Global Healthcare Conference qui se tiendra du 10 au 12 mars 2025 à l’adresse suivante : W Hotel South Beach, Miami, Floride. L’équipe de direction représentera la Société lors d'un fireside chat programmé le mardi 11 mars 2025 de 15h00 à 15h30 ET. La présentation sera retransmise en direct et disponible sur le internet de la Société à...
Innate Pharma to Participate in the 2025 Leerink Partners Global Healt...
MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team will present and host 1x1 meetings at the Leerink Partners 2025 Global Healthcare Conference being held on March 10 – 12, 2025 in W Hotel South Beach in Miami, Florida. The executive team will participate in a fireside chat scheduled Tuesday, March 11, 2025, from 3:00 - 3:30 pm ET. A live webcast and a replay of the presentation will be available on the page in the Investors section of website. About ...
Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designat...
MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody, for the treatment of adult patients with relapsed or refractory (r/r) Sézary Syndrome (SS) after at least 2 prior systemic therapies including mogamulizumab. The BTD is granted based on Phase 1 study results as well as results from the Phase 2 TELLOMAK study, where lacutamab demonstra...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.